Draw/line
Education and research purposes only, not medical advice. Unapproved compounds are not for human consumption. Check every result with your prescriber. Disclaimer Research and education only. Not medical advice. Disclaimer
Home / Compounds / Elamipretide

Elamipretide

Elamipretide (Forzinity, SS-31): its 2025 FDA accelerated approval for Barth syndrome, what the trials showed, known risks and sport status.

FDA-approved (accelerated), narrow use · Evidence grade B · Reviewed

Approved and studied uses
  • FDA-approvedBarth syndromeForzinity, accelerated approval 2025
  • Not approvedAging and energyNot approved; no proven benefit
Training and drug testingCheck the rules

WADA does not name elamipretide on its Prohibited List; athletes should check with their anti-doping organization.

Drug-tested athletes can look up any substance on Global DRO, run by national anti-doping agencies. Supplements can contain banned substances that are not on the label. Drawline does not suggest when to train or inject.

Elamipretide (Forzinity, SS-31, MTP-131, Bendavia). Mitochondria-targeted peptide.

BFDA-approved (accelerated), narrow use. Evidence grade B: human trials, narrow or pending approval.

What is Elamipretide?

Elamipretide is a small synthetic peptide that binds cardiolipin in the inner membrane of mitochondria, the parts of cells that make energy. It is given as a daily injection under the skin.

Is Elamipretide FDA-approved?

FDA granted accelerated approval to Forzinity (elamipretide) from Stealth BioTherapeutics on September 19, 2025, as the first treatment for Barth syndrome, a rare inherited mitochondrial disease. The approval is narrow: to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. It rests on gains in knee muscle strength, judged reasonably likely to predict real benefit, and FDA requires a confirmatory randomized trial. FDA had declined to review an earlier application filed in 2021.

What does the evidence show for Elamipretide?

Evidence is limited to very small studies. In the TAZPOWER trial the 12-week randomized part (12 patients) did not beat placebo on walking distance or fatigue; the strength gains came in a longer open-label extension. Claims for other uses, such as aging or general energy, have no proven human benefit.

What are the known risks of Elamipretide?

The most common side effects were mild to moderate injection site reactions, and serious reactions have been reported. It must not be used by people with serious allergy to any of its ingredients. Long-term safety is unknown because so few people have been studied. WADA does not name elamipretide on its Prohibited List; athletes should check with their anti-doping organization.

How is Elamipretide measured?

An approved injection: follow the product label and the prescriber.

Sources: FDA: FDA grants accelerated approval to first treatment for Barth syndrome; FDA Drug Trials Snapshots: Forzinity; FDA label: Forzinity (elamipretide), 2025. This profile does not recommend any dose or use.

For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.

Spot a mistake or an out-of-date fact? Report an error. We check every report against the sources.